Aamir Fahira, Zijia Zhu, Zhiqiang Li, Yongyong Shi
{"title":"仔细研究精神分裂症和维生素补充之间的因果关系:一项孟德尔随机研究","authors":"Aamir Fahira, Zijia Zhu, Zhiqiang Li, Yongyong Shi","doi":"10.1097/JBR.0000000000000104","DOIUrl":null,"url":null,"abstract":"Abstract Objective: Observational studies have reported malnutrition and vitamin deficiency in patients with schizophrenia (SZ), which can lead to serious metabolic syndromes and decrease anti-psychiatric drug outcomes. Whereas, vitamin intake along with psychiatric medication can enhance the medication outcomes. However, it is still unknown if SZ induces vitamin deficiency. Herein, we conduct the Mendelian randomization analysis to explore the causal relationship between schizophrenia and vitamins supplementation. Methods: We retrieved the genome-wide summary statistical data for schizophrenia from recent SZ GWAS data (43,175 cases and 65,166 controls) and vitamins supplementation GWAS data from Neale's GWAS datasets (more than 337,000 samples from the European population) and performed a two-sample Mendelian randomization analysis to determine the causal association of SZ with vitamin supplementation, in addition, we conduct the sensitivity analysis to obtain reliable results and remove confounding bias. Results: SZ have causal relationships with vitamins A, B, C, D, and E (SZ/vitamin A: β = 0.002, se = 0.001, 95% confidence interval (CI): 0.001 to 0.004, P = 1.41E-05, heterogeneity P = 0.4486; SZ/vitamin B: β = 0.004, se = 0.001, 95% CI: 0.002-0.005, P = 7.0E-05, heterogeneity P = 0.2217; SZ/vitamin C: β = 0.004, se = 0.001, 95% CI: 0.002-0.007, P = 0.001, heterogeneity P = 0.1349; SZ/vitamin D: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 0.001, heterogeneity P = 0.433; SZ/vitamin E: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 5.0E-05, heterogeneity P = 0.1382). Conclusion: Our findings suggest that vitamin levels and supplementation should be carefully controlled in patients with SZ, which in turn may enhance the therapeutic effects of antipsychotic drug treatments.","PeriodicalId":150904,"journal":{"name":"Journal of Bio-X Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Scrutinizing the causal relationship between schizophrenia and vitamin supplementation: a Mendelian randomization study\",\"authors\":\"Aamir Fahira, Zijia Zhu, Zhiqiang Li, Yongyong Shi\",\"doi\":\"10.1097/JBR.0000000000000104\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objective: Observational studies have reported malnutrition and vitamin deficiency in patients with schizophrenia (SZ), which can lead to serious metabolic syndromes and decrease anti-psychiatric drug outcomes. Whereas, vitamin intake along with psychiatric medication can enhance the medication outcomes. However, it is still unknown if SZ induces vitamin deficiency. Herein, we conduct the Mendelian randomization analysis to explore the causal relationship between schizophrenia and vitamins supplementation. Methods: We retrieved the genome-wide summary statistical data for schizophrenia from recent SZ GWAS data (43,175 cases and 65,166 controls) and vitamins supplementation GWAS data from Neale's GWAS datasets (more than 337,000 samples from the European population) and performed a two-sample Mendelian randomization analysis to determine the causal association of SZ with vitamin supplementation, in addition, we conduct the sensitivity analysis to obtain reliable results and remove confounding bias. Results: SZ have causal relationships with vitamins A, B, C, D, and E (SZ/vitamin A: β = 0.002, se = 0.001, 95% confidence interval (CI): 0.001 to 0.004, P = 1.41E-05, heterogeneity P = 0.4486; SZ/vitamin B: β = 0.004, se = 0.001, 95% CI: 0.002-0.005, P = 7.0E-05, heterogeneity P = 0.2217; SZ/vitamin C: β = 0.004, se = 0.001, 95% CI: 0.002-0.007, P = 0.001, heterogeneity P = 0.1349; SZ/vitamin D: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 0.001, heterogeneity P = 0.433; SZ/vitamin E: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 5.0E-05, heterogeneity P = 0.1382). Conclusion: Our findings suggest that vitamin levels and supplementation should be carefully controlled in patients with SZ, which in turn may enhance the therapeutic effects of antipsychotic drug treatments.\",\"PeriodicalId\":150904,\"journal\":{\"name\":\"Journal of Bio-X Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bio-X Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/JBR.0000000000000104\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bio-X Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JBR.0000000000000104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
摘要目的:观察性研究报道了精神分裂症(SZ)患者营养不良和维生素缺乏,这可能导致严重的代谢综合征和降低抗精神药物疗效。然而,在服用精神药物的同时摄入维生素可以提高治疗效果。然而,尚不清楚SZ是否会导致维生素缺乏。在此,我们通过孟德尔随机化分析来探讨精神分裂症与维生素补充之间的因果关系。方法:我们从最近的SZ GWAS数据(43,175例和65,166例对照)和Neale的GWAS数据集(来自欧洲人群的超过337,000个样本)中检索精神分裂症的全基因组汇总统计数据,并进行双样本孟德尔随机化分析以确定SZ与维生素补充的因果关系,此外,我们进行敏感性分析以获得可靠的结果并消除混杂偏倚。结果:SZ与维生素A、B、C、D、E之间存在因果关系(SZ/维生素A: β = 0.002, se = 0.001, 95%置信区间(CI): 0.001 ~ 0.004, P = 1.41E-05,异质性P = 0.4486;SZ/维生素B: β = 0.004, se = 0.001, 95% CI: 0.002 ~ 0.005, P = 7.0E-05,异质性P = 0.2217;SZ/维生素C: β = 0.004, se = 0.001, 95% CI: 0.002 ~ 0.007, P = 0.001,异质性P = 0.1349;SZ/维生素D: β = 0.003, se = 0.001, 95% CI: 0.002 ~ 0.005, P = 0.001,异质性P = 0.433;SZ/维生素E: β = 0.003, se = 0.001, 95% CI: 0.002 ~ 0.005, P = 5.0e ~ 05,异质性P = 0.1382)。结论:我们的研究结果表明,SZ患者应仔细控制维生素水平和补充,这反过来可能会提高抗精神病药物治疗的效果。
Scrutinizing the causal relationship between schizophrenia and vitamin supplementation: a Mendelian randomization study
Abstract Objective: Observational studies have reported malnutrition and vitamin deficiency in patients with schizophrenia (SZ), which can lead to serious metabolic syndromes and decrease anti-psychiatric drug outcomes. Whereas, vitamin intake along with psychiatric medication can enhance the medication outcomes. However, it is still unknown if SZ induces vitamin deficiency. Herein, we conduct the Mendelian randomization analysis to explore the causal relationship between schizophrenia and vitamins supplementation. Methods: We retrieved the genome-wide summary statistical data for schizophrenia from recent SZ GWAS data (43,175 cases and 65,166 controls) and vitamins supplementation GWAS data from Neale's GWAS datasets (more than 337,000 samples from the European population) and performed a two-sample Mendelian randomization analysis to determine the causal association of SZ with vitamin supplementation, in addition, we conduct the sensitivity analysis to obtain reliable results and remove confounding bias. Results: SZ have causal relationships with vitamins A, B, C, D, and E (SZ/vitamin A: β = 0.002, se = 0.001, 95% confidence interval (CI): 0.001 to 0.004, P = 1.41E-05, heterogeneity P = 0.4486; SZ/vitamin B: β = 0.004, se = 0.001, 95% CI: 0.002-0.005, P = 7.0E-05, heterogeneity P = 0.2217; SZ/vitamin C: β = 0.004, se = 0.001, 95% CI: 0.002-0.007, P = 0.001, heterogeneity P = 0.1349; SZ/vitamin D: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 0.001, heterogeneity P = 0.433; SZ/vitamin E: β = 0.003, se = 0.001, 95% CI: 0.002-0.005, P = 5.0E-05, heterogeneity P = 0.1382). Conclusion: Our findings suggest that vitamin levels and supplementation should be carefully controlled in patients with SZ, which in turn may enhance the therapeutic effects of antipsychotic drug treatments.